GAST and melanoma: Interestingly, the probability of elevated gastrin was significantly greater in the sub-group of melanoma patients with stage 2 (18 out of 44) compared with stage 1 (3 out of 42) disease (OR 8.5, p < 0.0005; Fisher exact test p < 0.0003) (Figure 2A).